Dividend investing eliminates sequence risk and provides a reliable source of income. Read more to see why dividends matter...
Continue ReadingLooking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results...
Continue ReadingDuring Q1 2024, the Patient Opportunity Equity representative account generated a total return of -1.9% net vs. S&P 500 Index return of 4.3%. Click here to read more...
Continue ReadingLooking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results...
Continue ReadingLooking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results...
Continue ReadingThe Blue Tower Global Value strategy composite had a relatively weak Q2 with a loss of -5.89% despite broad market indices having a gain...
Continue ReadingOpportunity Equity declined 1.9% net of fees in Q2 2024, taking our YTD return to 9.6% net of fees. Click here to read the full commentary...
Continue ReadingLooking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results...
Continue ReadingThe Magnificent Seven stocks have lost $1.13 trillion in market valuation in the prior five sessions. But there are two notable losers...
Continue ReadingLooking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results...
Continue Reading© 2026 Market News — All rights reserved